Notice2025-19376
Government Owned Inventions Available for Licensing and/or Collaboration: Acyloxyacyl Hydrolase (AOAH) and Methods of Use as a Cancer Immunotherapy
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 2, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the inventions listed below, which are owned by an agency of the U.S. Government and are available for licensing and/or collaboration to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 189 (Thursday, October 2, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 189 (Thursday, October 2, 2025)]
[Notices]
[Page 47782]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-19376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing and/or
Collaboration: Acyloxyacyl Hydrolase (AOAH) and Methods of Use as a
Cancer Immunotherapy
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health (NIH), Department of Health and Human
Services (HHS), is giving notice of the inventions listed below, which
are owned by an agency of the U.S. Government and are available for
licensing and/or collaboration to achieve expeditious commercialization
of results of federally-funded research and development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to these licensing
opportunities should be directed to: Kevin Chang, Ph.D., Technology
Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#690a0108070e020c290408000547070001470e061f"><span class="__cf_email__" data-cfemail="f3909b929d949896b39e929a9fdd9d9a9bdd949c85">[email protected]</span></a> or Phone: 240-276-6910.
SUPPLEMENTARY INFORMATION: Immune CheckPoint Inhibitors (ICIs) and T-
cell based therapies are part of the emerging immunology-based
therapies being used to treat cancers. However, the efficacy of ICI
therapies can be limited and a substantial portion of patients develop
resistance or tolerance to treatment. T-cell based cancer
immunotherapies have only been approved for hematological cancers. They
are suboptimal in solid tumor cancers due to physical barriers and the
immuno-suppressive tumor microenvironment. Thus, additional therapies
and strategies are needed to improve efficacy and expand the types of
cancer amendable to treatment.
Scientists at the NCI have identified a secreted lipase,
Acyloxyacyl Hydrolase (AOAH), produced by cells such as macrophages and
dendritic cells that can potentiate immunotherapies in murine tumor
models. The protein sensitizes T cell receptors to weak antigens and
protects dendritic cells through depleting immunosuppressive
arachidonyl phoshatidylcholines and oxidized derivatives. Thus, the
protein can potentially enhance the efficacy and types of cancers
treated by ICI based and T-cell based immunotherapies.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-038-2024.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology [verbar] Immunology.
Potential Commercial Applications:
<bullet> Cancer immunotherapy.
<bullet> Combination therapy with ICIs or T-cell based therapies.
Competitive Advantages:
<bullet> Novel therapeutic entity.
<bullet> Potentially improved efficacy.
<bullet> Increased types of addressable cancers.
Publication:
<bullet> Gong L et al. Cancer Immunology Data Engine Reveals
Secreted AOAH as a Potential Immunotherapy. (<a href="https://pubmed.ncbi.nlm.nih.gov/40730154/">https://pubmed.ncbi.nlm.nih.gov/40730154/</a>).
Patent Status: U.S. Provisional Patent Application entitled,
``Acyloxyacyl Hydrolase and Methods of Use'' was filed on November 6,
2024.
Development Stage: Pre-clinical (in vivo validation).
Collaboration Opportunity: The NCI seeks licensing and/or co-
development research collaborations for the development of AOAH as an
immunotherapy for cancer treatment.
Dated: September 30, 2025.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2025-19376 Filed 10-1-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 2, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.